Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (614)	11/5/2001 12:07:13 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

this could be a very good thing...... Monday November 5, 8:33 am Eastern Time Press Release SOURCE: Syrrx, Inc. Syrrx Appoints David Webb, Ph.D., Vice President of Drug Discovery Company Expands Drug Discovery Team in Line with Corporate Objectives SAN DIEGO--(BW HealthWire)--Nov. 5, 2001--Syrrx Inc. announced today the appointment of David R. Webb, Ph.D., as Vice President of Drug Discovery, in keeping with the company's objective to advance drug discovery efforts by the end of 2001. Syrrx also announced the expansion of its drug discovery research teams with the addition of several senior director and director level scientists. Under Dr. Webb's management, the drug discovery teams will leverage the company's high-throughput structural proteomics platform to further develop its pipeline of pre-clinical drug candidates. ``Dr. Webb's appointment to Syrrx strengthens our current drug discovery capabilities and will accelerate the processes of lead discovery, optimization and pre-clinical drug development,'' said Wendell Wierenga, Ph.D., Chief Executive Officer of Syrrx. ``His leadership will provide direction and vision for our medicinal and combinatorial chemistry teams in conjunction with our drug discovery program. Dr. Webb brings the leadership, creativity and scientific acumen to establish Syrrx as a premier drug discovery company.'' In addition to leading the drug discovery team at Syrrx, Dr. Webb will manage corporate partnerships involving drug discovery. He brings to Syrrx over 30 years of experience in the life sciences industry. Prior to joining Syrrx, Dr. Webb was Corporate Vice President of Discovery Research at OSI Pharmaceuticals Inc., where he was responsible for establishing the type II diabetes program, managing corporate alliances and overseeing the Functional Genomics, New Technologies and the Leads Discovery Groups. Dr. Webb served as Vice President of Research and Chief Scientific Officer at Cadus Pharmaceutical Corporation (Tarrytown, NY) from 1995-1999. He was Distinguished Scientist and Director of the Institute of Immunology and Biological Sciences at Syntex Inc. (Palo Alto, CA), from 1990-1995. ``The technologies developed at Syrrx represent a substantial advance for the field of rational drug discovery,'' Dr. Webb said. ``I look forward to working with my colleagues to blend these technologies into a new drug discovery paradigm that will help Syrrx advance in research-integrated pharmaceutical development.'' In addition to Dr. Webb's appointment as Vice President, Michael Tennant, Ph.D., was named the Director of Computational Biology. Dr. Tennant formerly worked as Senior Investigator, Computational and Structural Sciences at SmithKline Beecham Pharmaceuticals (Harlow, England). Newly appointed members of the Syrrx drug discovery team are: Marc Navre, Ph.D., Sr. Director of Leads Discovery, formerly Research Director of the Affymax Research Institute; Gideon Bollag, Ph.D., Director of Cellular Pharmacology, formerly the Senior Director, Small Molecule Therapeutics at Onyx Pharmaceuticals; and Xiao-Yi Xiao, Ph.D., Director of Combinatorial Chemistry, formerly the Director of Research Chemistry at ChemRx and IRORI, subsidiaries of Discovery Partners International. Syrrx Inc. is a science and technology-driven company redefining the way medicine is discovered. Based in San Diego, the company is the technology leader in the field of structural proteomics, the process of generating protein structures from genetic information. Syrrx uses its proprietary high-throughput ``gene to drug'' technology platform for rational discovery of new therapeutics. The company has formed a collaboration with Cubist Pharmaceuticals to discover and characterize new anti-infective drugs. More information about Syrrx and its partnerships can be found on the company's web site at syrrx.com. Contact: Syrrx, Inc. Rey Harmon, Corporate Communications 858/622-8528, ext. 4101 rey.harmon@syrrx.com or Susan E. Atkins & Associates Virginia Amann / Jason Spark 858/860-0266 vamann@irpr.com